Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held Sept. 14-16, 2026, in New York City. The webcast will take place on Sept. 14 at 9 a.m. EDT, with a replay available on the company's investor relations website.
This appearance comes at a pivotal time for the company, which recently rebranded as Helus Pharma, the commercial operating name of Cybin Inc. Helus Pharma is advancing a pipeline of proprietary NSAs designed to activate serotonin pathways believed to promote neuroplasticity, offering a potential new approach to treating depression and anxiety disorders. The company's lead candidate, HLP003, is in Phase 3 clinical development as an adjunctive treatment for major depressive disorder (MDD) and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder.
The announcement underscores the growing interest in psychedelic-inspired therapies for mental health. Unlike traditional antidepressants that often take weeks to show effects and may have limited efficacy, NSAs like HLP003 are designed to promote rapid and durable improvements in neuroplasticity, potentially offering a paradigm shift in how depression is treated. The Breakthrough Therapy Designation from the FDA highlights the potential of HLP003 to address a significant unmet medical need, given that a large proportion of patients with MDD do not achieve adequate response to existing treatments.
For business leaders and investors, this presentation is an opportunity to gain insight into the company's strategic direction, clinical progress, and the broader market potential of novel mental health treatments. Mental health conditions represent a substantial economic burden, with depression alone costing the global economy an estimated $1 trillion annually in lost productivity. If HLP003 and other NSAs succeed in clinical trials, they could offer new options for the millions of patients who have not found relief with current therapies, potentially reshaping the mental health treatment landscape.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland, and has an extensive research portfolio of investigational NSAs. The company's participation in the H.C. Wainwright conference signals its commitment to engaging with the investment community and keeping stakeholders informed about its development milestones. As the company moves closer to potential regulatory submissions, the outcomes of its ongoing trials will be closely watched by industry analysts and healthcare providers alike.
For more information about the fireside chat and to access the webcast, interested parties can visit the Events & Presentations page on Helus Pharma's investor relations website. The full press release is available at https://ibn.fm/1HSIo.
